羟基脲-话题@MedSci

#羟基脲#

10篇内容 | 1304人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2229630, encodeId=0ada222963098, content=<a href='/topic/show?id=660a80011c5' target=_blank style='color:#2F92EE;'>#羟基脲#</a> <a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a> <a href='/topic/show?id=acd5119903b4' target=_blank style='color:#2F92EE;'>#原发性血小板增多症（ET）#</a> <a href='/topic/show?id=109d119904ee' target=_blank style='color:#2F92EE;'>#IPSET#</a>, objectTitle=Leukemia：根据 IPSET 分层对原发性血小板增多症的一线羟基脲治疗反应的预后价值研究, objectType=article, longId=846023, objectId=6e378460233a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668018121539_4754896.png, objectUrl=/article/show_article.do?id=6e378460233a, replyNumber=0, likeNumber=58, createdTime=2024-10-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=6e378460233a, moduleTitle=Leukemia：根据 IPSET 分层对原发性血小板增多症的一线羟基脲治疗反应的预后价值研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e378460233a)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1441242, encodeId=5e22144124211, content=<a href='/topic/show?id=660a80011c5' target=_blank style='color:#2F92EE;'>#羟基脲#</a>, objectTitle=【Blood Adv】羟基脲治疗老年经典型MPN，不增加第二恶性肿瘤风险, objectType=article, longId=735271, objectId=3adbe352718e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3adbe352718e, replyNumber=0, likeNumber=89, createdTime=2022-08-10, rootId=0, userName=12498adam41暂无昵称, userId=53554807027, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3adbe352718e, moduleTitle=【Blood Adv】羟基脲治疗老年经典型MPN，不增加第二恶性肿瘤风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3adbe352718e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441241, encodeId=a349144124148, content=<a href='/topic/show?id=660a80011c5' target=_blank style='color:#2F92EE;'>#羟基脲#</a>, objectTitle=Blood：羟基脲 vs 聚乙二醇化IFN-α 治疗原发性血小板增多症/真性红细胞增多症, objectType=article, longId=727286, objectId=b019e27286d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b019e27286d3, replyNumber=0, likeNumber=94, createdTime=2022-05-20, rootId=0, userName=12498adam41暂无昵称, userId=53554807027, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b019e27286d3, moduleTitle=Blood：羟基脲 vs 聚乙二醇化IFN-α 治疗原发性血小板增多症/真性红细胞增多症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b019e27286d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441240, encodeId=8845144124035, content=<a href='/topic/show?id=660a80011c5' target=_blank style='color:#2F92EE;'>#羟基脲#</a>, objectTitle=NEJM：镰状细胞贫血羟基脲治疗剂量差异研究, objectType=article, longId=196475, objectId=13821964e514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13821964e514, replyNumber=0, likeNumber=0, createdTime=2020-06-27, rootId=0, userName=12498adam41暂无昵称, userId=53554807027, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13821964e514, moduleTitle=NEJM：镰状细胞贫血羟基脲治疗剂量差异研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13821964e514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441239, encodeId=577314412391e, content=<a href='/topic/show?id=660a80011c5' target=_blank style='color:#2F92EE;'>#羟基脲#</a>, objectTitle=Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！, objectType=article, longId=187425, objectId=b82918e4252e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b82918e4252e, replyNumber=0, likeNumber=118, createdTime=2020-02-06, rootId=0, userName=12498adam41暂无昵称, userId=53554807027, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b82918e4252e, moduleTitle=Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b82918e4252e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441238, encodeId=f9c4144123851, content=<a href='/topic/show?id=660a80011c5' target=_blank style='color:#2F92EE;'>#羟基脲#</a>, objectTitle=Blood：鲁索替尼也不能改善预后不良的高危型羟基脲耐受性ET患者的预后, objectType=article, longId=180563, objectId=8013180563df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8013180563df, replyNumber=0, likeNumber=85, createdTime=2019-10-07, rootId=0, userName=12498adam41暂无昵称, userId=53554807027, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8013180563df, moduleTitle=Blood：鲁索替尼也不能改善预后不良的高危型羟基脲耐受性ET患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8013180563df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441237, encodeId=9d61144123efa, content=<a href='/topic/show?id=660a80011c5' target=_blank style='color:#2F92EE;'>#羟基脲#</a>, objectTitle=Blood：羟基脲可减轻镰状细胞性贫血患者的脑代谢压力, objectType=article, longId=162670, objectId=3dd61626e077, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dd61626e077, replyNumber=0, likeNumber=83, createdTime=2019-03-22, rootId=0, userName=12498adam41暂无昵称, userId=53554807027, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dd61626e077, moduleTitle=Blood：羟基脲可减轻镰状细胞性贫血患者的脑代谢压力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dd61626e077)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441236, encodeId=b9bc14412369d, content=<a href='/topic/show?id=660a80011c5' target=_blank style='color:#2F92EE;'>#羟基脲#</a>, objectTitle=NEJM：羟基脲用于撒哈拉以南非洲国家儿童镰状细胞贫血, objectType=article, longId=157833, objectId=1f6e15e833b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6e15e833b5, replyNumber=0, likeNumber=83, createdTime=2019-01-13, rootId=0, userName=12498adam41暂无昵称, userId=53554807027, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6e15e833b5, moduleTitle=NEJM：羟基脲用于撒哈拉以南非洲国家儿童镰状细胞贫血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f6e15e833b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441235, encodeId=51f61441235cf, content=<a href='/topic/show?id=660a80011c5' target=_blank style='color:#2F92EE;'>#羟基脲#</a>, objectTitle=羟基脲致下肢溃疡一例, objectType=article, longId=154292, objectId=5fcd15429242, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fcd15429242, replyNumber=0, likeNumber=82, createdTime=2018-11-25, rootId=0, userName=12498adam41暂无昵称, userId=53554807027, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fcd15429242, moduleTitle=羟基脲致下肢溃疡一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fcd15429242)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441234, encodeId=2ec01441234a0, content=<a href='/topic/show?id=660a80011c5' target=_blank style='color:#2F92EE;'>#羟基脲#</a>, objectTitle=J Clin Oncol:原发性血小板增多症：羟基脲与阿司匹林联用效果如何？, objectType=article, longId=149862, objectId=829b14986267, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=829b14986267, replyNumber=0, likeNumber=73, createdTime=2018-09-30, rootId=0, userName=12498adam41暂无昵称, userId=53554807027, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=829b14986267, moduleTitle=J Clin Oncol:原发性血小板增多症：羟基脲与阿司匹林联用效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=829b14986267)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1441233, encodeId=14571441233fc, content=<a href='/topic/show?id=660a80011c5' target=_blank style='color:#2F92EE;'>#羟基脲#</a>, objectTitle=Am J Hematol：羟基脲治疗真红细胞增多症有证据了, objectType=article, longId=124754, objectId=d7e4124e549e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7e4124e549e, replyNumber=0, likeNumber=106, createdTime=2017-12-28, rootId=0, userName=12498adam41暂无昵称, userId=53554807027, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7e4124e549e, moduleTitle=Am J Hematol：羟基脲治疗真红细胞增多症有证据了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7e4124e549e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

羟基脲

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#羟基脲# #预后价值# #原发性血小板增多症（ET）# #IPSET#

Leukemia：根据 IPSET 分层对原发性血小板增多症的一线羟基脲治疗反应的预后价值研究

2024-10-07发表于上海

12498adam41暂无昵称 (审核中...)

前往app查看评论内容

#羟基脲#

【Blood Adv】羟基脲治疗老年经典型MPN，不增加第二恶性肿瘤风险

2022-08-10

12498adam41暂无昵称 (审核中...)

前往app查看评论内容

#羟基脲#

Blood：羟基脲 vs 聚乙二醇化IFN-α 治疗原发性血小板增多症/真性红细胞增多症

2022-05-20

12498adam41暂无昵称 (审核中...)

前往app查看评论内容

#羟基脲#

NEJM：镰状细胞贫血羟基脲治疗剂量差异研究

2020-06-27

12498adam41暂无昵称 (审核中...)

前往app查看评论内容

#羟基脲#

Lancet haematol：Ropeginterferon alfa-2b对比羟基脲用于真性红细胞增多症的长期疗效！

2020-02-06

12498adam41暂无昵称 (审核中...)

前往app查看评论内容

#羟基脲#

Blood：鲁索替尼也不能改善预后不良的高危型羟基脲耐受性ET患者的预后

2019-10-07

12498adam41暂无昵称 (审核中...)

前往app查看评论内容

#羟基脲#

Blood：羟基脲可减轻镰状细胞性贫血患者的脑代谢压力

2019-03-22

12498adam41暂无昵称 (审核中...)

前往app查看评论内容

#羟基脲#

NEJM：羟基脲用于撒哈拉以南非洲国家儿童镰状细胞贫血

2019-01-13

12498adam41暂无昵称 (审核中...)

前往app查看评论内容

#羟基脲#

羟基脲致下肢溃疡一例

2018-11-25

12498adam41暂无昵称 (审核中...)

前往app查看评论内容

#羟基脲#

J Clin Oncol:原发性血小板增多症：羟基脲与阿司匹林联用效果如何？

2018-09-30

12498adam41暂无昵称 (审核中...)

前往app查看评论内容

#羟基脲#

Am J Hematol：羟基脲治疗真红细胞增多症有证据了

2017-12-28

科室
- - 订阅+
  - 更多科室
工具
服务